Tech Company Financing Transactions
F2G Funding Round
F2G secured a $100 million investment round on 9/12/2024. Investors included AMR Action Fund, Johnson & Johnson Development Corporation and Novo Holdings.
Transaction Overview
Company Name
Announced On
9/12/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The latest round would help the UK-based company complete a global late-stage study of its lead drug, olorofim.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Lankro Way Eccles
Manchester, M30 0LX
UK
Manchester, M30 0LX
UK
Phone
Website
Email Address
Overview
F2G is a world leading UK biotech company focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections, with experienced management and board. F2G has discovered and developed a completely new class of antifungal agents called the orotomides.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ian Nicholson
Chief Financial Officer
Ralf Schmid
Chief Medical Officer
Emma Harvey
Chief Medical Officer
John Rex
Chief Operating Officer
Michael Birch
Chief Scientific Officer
Tony Kennedy
Browse more venture capital transactions:
Prev: 9/12/2024: Battolyser Systems venture capital transaction
Next: 9/12/2024: Inflammatix venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs